ScreenerHero

ATTO Attovia Therapeutics, Inc.

Partial data
NYSE · US · Healthcare · Biotechnology · attovia.com
18.21USD-14.51%Mkt Cap: 972.37M $P/E: —

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap972.37M USD
Enterprise Value976.90M USD
Revenue (TTM)1.80M USD
Gross Profit-62.46M USD
Net Income (TTM)-60.63M USD
Revenue/Share0.44 USD
Last Price18.21 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees44
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.63
PEG—
EV/EBITDA-12.98
EV/Revenue542.72
P/S460.82
P/B-0.57
EPS (TTM)-1.64
EPS (Forward)-2.38
52W Range
16.1517% of range28.00
52W High28.00 USD
52W Low16.15 USD
Profitability
Gross Margin0.00%
Oper. Margin-4845.11%
EBITDA Margin0.00%
Profit Margin-4490.89%
ROE56.43%
ROA-36.55%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-59.20M USD
CapEx (TTM)2.31M USD
FCF Margin—
FCF Yield—
Net Debt-110.81M USD
Net Debt/EBITDA1.47
Balance Sheet
Debt/Equity-0.05
Current Ratio9.39
Quick Ratio9.20
Book Value/Sh-32.12 USD
Cash/Share2.52 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)42.20 USD
Upside (mean)+131.8%
Target Range30.00 USD – 52.00 USD
30.00+131.8% to mean52.00
# Analysts5
Ownership
Shares Out.45.65M
Float26.26M
Insiders8.85%
Institutions40.87%
Short Interest
Short Ratio0.5d
Short % Out.1.42%
Shares Short511.87K
Technical
SMA 5021.52 (-15.4%)
SMA 20021.52 (-15.4%)
Beta—
S&P 52W Chg16.67%
Avg Vol (30d)292.12K
Avg Vol (10d)426.53K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—